Tick-borne encephalitis vaccine breakthrough infections induce aberrant T cell and antibody responses to non-structural proteins.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
07 Aug 2024
07 Aug 2024
Historique:
received:
22
03
2024
accepted:
17
07
2024
medline:
8
8
2024
pubmed:
8
8
2024
entrez:
7
8
2024
Statut:
epublish
Résumé
Tick-borne encephalitis virus (TBEV) vaccine breakthrough (VBT) infections are not uncommon in endemic areas. The clinical and immunological outcomes have been poorly investigated. We assessed the magnitude and specificity of virus-specific antibody and T cell responses after TBE in previously vaccinated subjects and compared the results with those of unvaccinated TBE patients and study subjects that received vaccination without VBT infection. Symptomatic TBEV infection of unvaccinated study subjects induced virus-specific antibody responses to the E protein and non-structural protein 1 (NS1) as well as T cell responses to structural and other non-structural (NS) proteins. After VBT infections, significantly impaired NS1-specific antibody responses were observed, while the virus-specific T cell responses to the NS proteins were relatively strong. VBT infection caused predominantly moderate to severe disease during hospitalization. The level of TBEV EDIII- and NS1-specific antibodies in unvaccinated convalescent patients inversely correlated with TBE severity and neurological symptoms early after infection.
Identifiants
pubmed: 39112523
doi: 10.1038/s41541-024-00936-7
pii: 10.1038/s41541-024-00936-7
doi:
Types de publication
Journal Article
Langues
eng
Pagination
141Subventions
Organisme : Alexander von Humboldt-Stiftung (Alexander von Humboldt Foundation)
ID : NA
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 848166
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 848166
Organisme : The Slovenian Research and Innovation Agency (ARIS)
ID : P3-0083
Organisme : The Slovenian Research and Innovation Agency (ARIS)
ID : P3-0296
Organisme : The Slovenian Research and Innovation Agency (ARIS)
ID : J3-3063
Organisme : The Slovenian Research and Innovation Agency (ARIS)
ID : P3-0083
Organisme : The Slovenian Research and Innovation Agency (ARIS)
ID : P3-0296
Organisme : The Slovenian Research and Innovation Agency (ARIS)
ID : J3-3063
Organisme : Univerza v Ljubljani (University of Ljubljana)
ID : MRIC-UL-IC-BSL3+
Organisme : Univerza v Ljubljani (University of Ljubljana)
ID : MRIC-UL-IC-BSL3+
Organisme : Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)
ID : 01KI1719
Organisme : Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)
ID : 01KI1719
Informations de copyright
© 2024. The Author(s).
Références
Ruzek, D. et al. Tick-borne encephalitis in Europe and Russia: review of pathogenesis, clinical features, therapy, and vaccines. Antivir. Res. 164, 23–51 (2019).
pubmed: 30710567
doi: 10.1016/j.antiviral.2019.01.014
Simmonds, P. et al. ICTV virus taxonomy profile: flaviviridae. J. Gen. Virol. 98, 2–3 (2017).
pubmed: 28218572
pmcid: 5370391
doi: 10.1099/jgv.0.000672
Slon Campos, J. L., Mongkolsapaya, J. & Screaton, G. R. The immune response against flaviviruses. Nat. Immunol. 19, 1189–1198 (2018).
pubmed: 30333606
doi: 10.1038/s41590-018-0210-3
Hombach, J., Barrett, A. D. & Kollaritsch, H. in Plotkin’s Vaccines 1080–1094 (Elsevier, 2018).
Bogovic, P. & Strle, F. Tick-borne encephalitis: a review of epidemiology, clinical characteristics, and management. World J. Clin. Cases 3, 430–441 (2015).
pubmed: 25984517
pmcid: 4419106
doi: 10.12998/wjcc.v3.i5.430
Wagner, J. N. et al. Patients with breakthrough tick-borne encephalitis suffer a more severe clinical course and display extensive magnetic resonance imaging changes. Eur. J. Neurol. 27, 1201–1209 (2020).
pubmed: 32324925
doi: 10.1111/ene.14276
Hansson, K. E. et al. Tick-borne encephalitis vaccine failures: a 10-year retrospective study supporting the rationale for adding an extra priming dose in individuals starting at age 50 years. Clin. Infect. Dis. 70, 245–251 (2020).
pubmed: 30843030
doi: 10.1093/cid/ciz176
Heinz, F. X. et al. Vaccination and tick-borne encephalitis, central Europe. Emerg. Infect. Dis. 19, 69–76 (2013).
pubmed: 23259984
pmcid: 3557984
doi: 10.3201/eid1901.120458
Lenhard, T. et al. Clinical outcome and cerebrospinal fluid profiles in patients with tick-borne encephalitis and prior vaccination history. Ticks Tick Borne Dis. 9, 882–888 (2018).
pubmed: 29576392
doi: 10.1016/j.ttbdis.2018.02.021
Fares, W. et al. Tick-borne encephalitis virus in Ixodes ricinus (Acari: Ixodidae) ticks, Tunisia. Ticks Tick Borne Dis. 12, 101606 (2021).
pubmed: 33189912
doi: 10.1016/j.ttbdis.2020.101606
Mansbridge, C. T. et al. Autochthonous tick-borne encephalitis in the United Kingdom: a second probable human case and local eco-epidemiological findings. Ticks Tick Borne Dis. 13, 101853 (2022).
pubmed: 34670189
doi: 10.1016/j.ttbdis.2021.101853
Lindenbach, B. D. & Rice, C. M. Molecular biology of flaviviruses. Adv. Virus Res. 59, 23–61 (2003).
pubmed: 14696326
doi: 10.1016/S0065-3527(03)59002-9
Ergunay, K., Tkachev, S., Kozlova, I. & Růžek, D. A review of methods for detecting tick-borne encephalitis virus infection in tick, animal, and human specimens. Vector Borne Zoonotic Dis. 16, 4–12 (2016).
pubmed: 26771446
doi: 10.1089/vbz.2015.1896
Agudelo, M. et al. Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease. J. Exp. Med. 218, e20210236 (2021).
pubmed: 33831141
pmcid: 8040517
doi: 10.1084/jem.20210236
Beicht, J. et al. Induction of humoral and cell-mediated immunity to the NS1 protein of TBEV with recombinant Influenza virus and MVA affords partial protection against lethal TBEV infection in mice. Front. Immunol. 14, 1177324 (2023).
pubmed: 37483628
pmcid: 10360051
doi: 10.3389/fimmu.2023.1177324
Stiasny, K., Leitner, A., Holzmann, H. & Heinz, F. X. Dynamics and extent of non-structural protein 1-antibody responses in tick-borne encephalitis vaccination breakthroughs and unvaccinated patients. Viruses 13, 1007 (2021).
pubmed: 34072119
pmcid: 8228328
doi: 10.3390/v13061007
Albinsson, B. et al. Distinction between serological responses following tick-borne encephalitis virus (TBEV) infection vs vaccination, Sweden 2017. Eur. Surveill. 23, 17–00838 (2018).
doi: 10.2807/1560-7917.ES.2018.23.3.17-00838
Lotrič-Furlan, S. et al. Tick-borne encephalitis in patients vaccinated against this disease. J. Intern. Med. 282, 142–155 (2017).
pubmed: 28440879
doi: 10.1111/joim.12625
Stiasny, K., Holzmann, H. & Heinz, F. X. Characteristics of antibody responses in tick-borne encephalitis vaccination breakthroughs. Vaccine 27, 7021–7026 (2009).
pubmed: 19789092
doi: 10.1016/j.vaccine.2009.09.069
Andersson, C. R. et al. Vaccine failures after active immunisation against tick-borne encephalitis. Vaccine 28, 2827–2831 (2010).
pubmed: 20167301
doi: 10.1016/j.vaccine.2010.02.001
Pavletič, M. et al. Upregulated intrathecal expression of VEGF-A and long lasting global upregulation of proinflammatory immune mediators in vaccine breakthrough tick-borne encephalitis. Front. Cell Infect. Microbiol. 11, 696337 (2021).
pubmed: 34277474
pmcid: 8281926
doi: 10.3389/fcimb.2021.696337
Marušić, M. et al. Dendritic cell activation and cytokine response in vaccine breakthrough TBE patients after in vitro stimulation with TBEV. Front. Immunol. 14, 1190803 (2023).
pubmed: 37261350
pmcid: 10228714
doi: 10.3389/fimmu.2023.1190803
Blom, K. et al. Specificity and dynamics of effector and memory CD8 T cell responses in human tick-borne encephalitis virus infection. PLoS Pathog. 11, e1004622 (2015).
pubmed: 25611738
pmcid: 4303297
doi: 10.1371/journal.ppat.1004622
Blom, K. et al. Cell-mediated immune responses and immunopathogenesis of human tick-borne encephalitis virus-infection. Front. Immunol. 9, 2174 (2018).
pubmed: 30319632
pmcid: 6168641
doi: 10.3389/fimmu.2018.02174
Lampen, M. H. et al. Breadth and dynamics of HLA-A2- and HLA-B7-restricted CD8(+) T cell responses against nonstructural viral proteins in acute human tick-borne encephalitis virus infection. Immunohorizons 2, 172–184 (2018).
pubmed: 31022685
doi: 10.4049/immunohorizons.1800029
Bogovič, P. et al. The long-term outcome of tick-borne encephalitis in Central Europe. Ticks Tick Borne Dis. 9, 369–378 (2018).
pubmed: 29275872
doi: 10.1016/j.ttbdis.2017.12.001
Bogovic, P., Logar, M., Avsic-Zupanc, T., Strle, F. & Lotric-Furlan, S. Quantitative evaluation of the severity of acute illness in adult patients with tick-borne encephalitis. Biomed. Res. Int. 2014, 841027 (2014).
pubmed: 24895617
pmcid: 4033426
doi: 10.1155/2014/841027
Aberle, J. H. et al. Human CD4+ T helper cell responses after tick-borne encephalitis vaccination and infection. PLoS ONE 10, e0140545 (2015).
pubmed: 26465323
pmcid: 4605778
doi: 10.1371/journal.pone.0140545
Schwaiger, J. et al. Specificities of human CD4+ T cell responses to an inactivated flavivirus vaccine and infection: correlation with structure and epitope prediction. J. Virol. 88, 7828–7842 (2014).
pubmed: 24789782
pmcid: 4097808
doi: 10.1128/JVI.00196-14
Bogovič, P. et al. Low virus-specific IgG antibodies in adverse clinical course and outcome of tick-borne encephalitis. Microorganisms 9, 332 (2021).
pubmed: 33562267
pmcid: 7914885
doi: 10.3390/microorganisms9020332
Kubinski, M. et al. A recombinant Modified Vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infection. Front. Immunol. 14, 1182963 (2023).
pubmed: 37153588
pmcid: 10160477
doi: 10.3389/fimmu.2023.1182963
Kubinski, M. et al. Cross-reactive antibodies against Langat virus protect mice from lethal tick-borne encephalitis virus infection. Front. Immunol. 14, 1134371 (2023).
pubmed: 36926332
pmcid: 10011100
doi: 10.3389/fimmu.2023.1134371
Könenkamp, L., Ziegler, U., Naucke, T., Groschup, M. H. & Steffen, I. Antibody ratios against NS1 antigens of tick-borne encephalitis and West Nile viruses support differential flavivirus serology in dogs. Transbound. Emerg. Dis. 69, e2789–e2799 (2022).
pubmed: 35704505
doi: 10.1111/tbed.14630
Steffen, R., Erber, W. & Schmitt, H. J. Can the booster interval for the tick-borne encephalitis (TBE) vaccine ‘FSME-IMMUN’ be prolonged? - A systematic review. Ticks Tick Borne Dis. 12, 101779 (2021).
pubmed: 34298356
doi: 10.1016/j.ttbdis.2021.101779
Beran, J., Lattanzi, M., Xie, F., Moraschini, L. & Galgani, I. Second five-year follow-up after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10 years antibody persistence. Vaccine 37, 4623–4629 (2019).
pubmed: 29397225
doi: 10.1016/j.vaccine.2017.12.081
Erber, W. et al. Effectiveness of TBE vaccination in southern Germany and Latvia. Vaccine 40, 819–825 (2022).
pubmed: 34952753
doi: 10.1016/j.vaccine.2021.12.028
Salat, J. et al. Tick-borne encephalitis virus vaccines contain non-structural protein 1 antigen and may elicit NS1-specific antibody responses in vaccinated individuals. Vaccines 8, 81 (2020).
pubmed: 32059489
pmcid: 7157539
doi: 10.3390/vaccines8010081
Ackermann-Gäumann, R. et al. Vaccination against tick-borne encephalitis elicits a detectable NS1 IgG antibody response. J. Virol. Methods 322, 114831 (2023).
pubmed: 37838083
doi: 10.1016/j.jviromet.2023.114831
Bogovič, P., Lotrič-Furlan, S., Avšič-Županc, T., Lusa, L. & Strle, F. Factors associated with severity of tick-borne encephalitis: a prospective observational study. Travel Med. Infect. Dis. 26, 25–31 (2018).
pubmed: 30296483
doi: 10.1016/j.tmaid.2018.10.003
Puerta-Guardo, H. et al. Flavivirus NS1 triggers tissue-specific disassembly of intercellular junctions leading to barrier dysfunction and vascular leak in a GSK-3β-dependent manner. Pathogens 11, 615 (2022).
pubmed: 35745469
pmcid: 9228372
doi: 10.3390/pathogens11060615
Beatty, P. R. et al. Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. Sci. Transl. Med. 7, 304ra141 (2015).
pubmed: 26355030
doi: 10.1126/scitranslmed.aaa3787
Mannik, M., Arend, M. P., Hall, A. P. & Gilliland, B. C. Studies on antigen-antibody complexes. I. Elimination of soluble complexes from rabbit circulation. J. Exp. Med. 133, 713–739 (1971).
pubmed: 5547056
pmcid: 2138971
doi: 10.1084/jem.133.4.713
Yu, L. et al. Delineating antibody recognition against Zika virus during natural infection. JCI Insight 2, e93042 (2017).
pubmed: 28614803
pmcid: 5470883
doi: 10.1172/jci.insight.93042
Schlesinger, J. J., Brandriss, M. W. & Walsh, E. E. Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48. J. Immunol. 135, 2805–gp2809 (1985).
pubmed: 4031501
doi: 10.4049/jimmunol.135.4.2805
Henchal, E. A., Henchal, L. S. & Schlesinger, J. J. Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. J. Gen. Virol. 69, 2101–2107 (1988).
pubmed: 3404125
doi: 10.1099/0022-1317-69-8-2101
Chung, K. M. et al. Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J. Virol. 80, 1340–1351 (2006).
pubmed: 16415011
pmcid: 1346945
doi: 10.1128/JVI.80.3.1340-1351.2006
Aregay, A. et al. Poor virus-specific T-cell responses early after tick-borne encephalitis virus infection correlate with disease severity. Emerg. Microbes Infect. 13, 2317909 (2024).
pmcid: 10883091
doi: 10.1080/22221751.2024.2317909
Varnaitė, R. et al. Magnitude and functional profile of the human CD4(+) T cell response throughout primary immunization with tick-borne encephalitis virus vaccine. J. Immunol. 204, 914–922 (2020).
pubmed: 31924650
doi: 10.4049/jimmunol.1901115